Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a
portfolio of checkpoint modulators (CPMs), heat shock protein
peptide-based vaccines, and adjuvants, today announced that Garo Armen,
PhD, Chief Executive Officer, and Robert Stein, MD, PhD, Chief
Scientific Officer, will conduct a series of one-on-one meetings with
investors at the FBR Inaugural Healthcare Conference on Wednesday,
September 3 in Boston.
Agenus management will also present a Company overview at the Rodman &
Renshaw 16th Annual Healthcare Conference in New York City on
Tuesday, September 9 at 9:10 a.m. EDT.
Webcast Information
The live and archived webcast of the presentation will be accessible
from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to ensure a
timely connection. The archived replay will be available on the Agenus
website for one month following the conference.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants.
Agenus’ checkpoint modulator programs target GITR, OX40, LAG-3, TIM-3,
CTLA-4 and PD-1, critical targets in co-stimulatory and inhibitory
pathways regulating self-tolerance and immune responses to tumor
antigens. Checkpoint modulators represent an important new class of
cancer immunotherapeutics. The Company’s proprietary discovery engine,
Retrocyte Display,® is used to generate fully human and
humanized therapeutic antibody drug candidates. The Retrocyte Display
platform uses IgG format human antibody libraries expressed in mammalian
B-lineage cells, to generate antibodies with high potency and
specificity, and with no re-engineering requirement. Agenus’ Prophage
heat shock protein vaccines recently generated positive data in phase 2
studies in newly diagnosed gliobastoma (the most common and most
aggressive malignant primary brain cancer) and in genital herpes (an
incurable infectious disease afflicting over 40 million adults in the
United States). The Company’s QS-21 Stimulon® adjuvant is a
key component in the development of several investigational vaccines
across a wide variety of infectious diseases, and therapeutic vaccines
intended to treat cancer and degenerative disorders. The QS-21 platform
is extensively partnered with GlaxoSmithKline and Janssen and includes
two candidates in phase 3 trials for melanoma and shingles. A regulatory
application was filed recently by GlaxoSmithKline with the EMA, and has
been accepted for review, following positive results in a phase 3 trial
in malaria. For more information, please visit www.agenusbio.com,
or connect with the company on Facebook, LinkedIn, Twitter and Google+.
For more information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements, including
statements regarding the Company’s upcoming corporate presentation.
These forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks and
uncertainties include, among others, the factors described under the
Risk Factors section of our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission for the period ended June 30, 2014.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These statements
speak only as of the date of this document, and Agenus undertakes no
obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement. Agenus’ business is subject to substantial risks and
uncertainties, including those identified above. When evaluating Agenus’
business and securities, investors should give careful consideration to
these risks and uncertainties.
Copyright Business Wire 2014